Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans

Nat Med. 2009 Aug;15(8):873-5. doi: 10.1038/nm.1991. Epub 2009 Jul 20.


The immunologic basis for the potential enhanced HIV-1 acquisition in adenovirus serotype 5 (Ad5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5-seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5-seronegative subjects after vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / immunology*
  • AIDS Vaccines / therapeutic use*
  • Acquired Immunodeficiency Syndrome / immunology
  • Acquired Immunodeficiency Syndrome / therapy*
  • Adenoviridae / immunology*
  • Antibodies, Viral / analysis
  • Antibodies, Viral / blood
  • Antibody Specificity / immunology
  • HIV-1 / immunology*
  • Humans
  • Immunization
  • Interferon-gamma / metabolism
  • T-Cell Antigen Receptor Specificity / immunology
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism
  • Vaccines, Synthetic / immunology
  • Vaccines, Synthetic / therapeutic use


  • AIDS Vaccines
  • Antibodies, Viral
  • Vaccines, Synthetic
  • Interferon-gamma